Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation

Transplantation

Volumn 98, Issue 8, 2014, Pages 857-863

  Orandi, Babak J ^a   Zachary, Andrea A ^a   Dagher, Nabil N ^a   Bagnasco, Serena M ^a   Garonzik Wang, Jacqueline M ^a   Van Arendonk, Kyle J ^a   Gupta, Natasha ^a   Lonze, Bonnie E ^a   Alachkar, Nada ^a   Kraus, Edward S ^a   Desai, Niraj M ^a   Locke, Jayme E ^b   Racusen, Lorraine C ^a   Segev, Dorry L ^a   Montgomery, Robert A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Kentucky   (United States)

Author keywords

Antibody mediated rejection; Complement inhibition; HLA incompatible kidney transplantation; Intravenous immunoglobulin; Rescue immunosuppressive regimens

Indexed keywords

ANTIBODY; CREATININE; DONOR SPECIFIC ANTIBODY; ECULIZUMAB; UNCLASSIFIED DRUG; ALLOANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DESENSITIZATION; FEMALE; GLOMERULOPATHY; GRAFT FAILURE; HISTOINCOMPATIBILITY; HLA SYSTEM; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OLIGURIA; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SPLENECTOMY; YOUNG ADULT; BIOPSY; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY; PATHOLOGY; POSTOPERATIVE COMPLICATIONS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SALVAGE THERAPY; SPLENECTOMY;

EID: 84922014185     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000298     Document Type: Article

References (22)

1. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
2. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
3. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant 2008; 8: 492.
4. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
5. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4: 996.
6. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
7. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842.
8. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256.
9. Kaplan B, Gangemi A, Thielke J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83: 99.
10. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant 2012; 12: 1643.
11. KaplanB, JieT, Diana R, etal. Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. Am J Transplant 2010;10: 1316.
12. Tzvetanov I, Spaggiari M, Oberholzer J, et al. Cell population in spleens during antibody-mediated rejection: pathologic and clinical findings. Transplantation 2012; 94: 255.
13. Wang H, Arp J, Liu W, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007; 179: 4451.
14. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231.
15. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405.
16. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24: e61.
17. Gonzalez-Roncero F, Suner M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012; 44: 2690.
18. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012; 12: 2546.
19. Hamer R, Krishnan N, Lowe D, et al. C5b-9 inhibitor (eculizumab) for antibody-mediated rejection in renal transplantation. Indian J Transplant 2011; 5: 6.
20. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744.
21. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaVan addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.